ILiAD Biotechnologies closed an oversubscribed $115 million Series B led by RA Capital to advance BPZE1, a live attenuated intranasal pertussis vaccine, into Phase III and pivotal human challenge studies. BPZE1 is designed to elicit both mucosal and systemic immunity and to improve protection against Bordetella pertussis transmission and disease. The company plans to begin a pivotal human challenge study in 2026 with initial data targeted for 2027. Investors highlighted the unmet global need for more durable pertussis vaccines and the operational advantages of a needle‑free intranasal platform. ILiAD said the proceeds will underwrite late‑stage development and scale activities ahead of potential registrational pathways.